Primary Biliary Cholangitis clinical trials

Explore recruiting primary biliary cholangitis clinical trials.

Recruiting primary biliary cholangitis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Primary Biliary Cholangitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis

Netherlands, France, Norway, Hungary, Italy, Lithuania +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants With Primary Biliary Cholangitis (PBC)

Belgium, Italy, Romania, Spain, Czechia, France +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic Acid

Belgium, Spain, France, Germany, Italy

Phase II and Phase III (Integrated) EU CTIS Study details

AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Germany, Italy, France, Hungary, Greece, Czechia +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Czechia, Belgium, Spain, Hungary, Italy, Netherlands +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination with Obeticholic Acid in Subjects with Primary Biliary Cholangitis

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Primary Biliary Cholangitis trials by city

Primary Biliary Cholangitis in Toronto Primary Biliary Cholangitis in Vancouver Primary Biliary Cholangitis in Montreal Primary Biliary Cholangitis in Calgary Primary Biliary Cholangitis in Edmonton Primary Biliary Cholangitis in Ottawa Primary Biliary Cholangitis in Winnipeg Primary Biliary Cholangitis in Quebec City Primary Biliary Cholangitis in Hamilton Primary Biliary Cholangitis in Kitchener Primary Biliary Cholangitis in London Primary Biliary Cholangitis in Halifax Primary Biliary Cholangitis in New York Primary Biliary Cholangitis in Los Angeles Primary Biliary Cholangitis in Chicago Primary Biliary Cholangitis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease